newsfilter
← Latest News
GlobeNewswire·

VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update

2023 was a transformative year for VYNE, marked by the achievement of clinical proof-of-concept for VYN201 in vitiligo and a successful financing with a syndicate of leading institutional investorsAnticipate commencing a